Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Tourmaline Bio

    Healthcare setting

    Clinical research in 2026: The trends shaping tomorrow

    Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

    Cuttsy + Cuttsy

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Kymera reports positive results in clinical trial for atopic dermatitis

    KT-621 could become a first-in-class, once-a-day oral treatment

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    Printed version of 'The participation equation'

    Behind the scenes: why we created ‘The participation equation’

    Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

    Cuttsy + Cuttsy

    R:SQD logo

    Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success

    Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.

    Cuttsy + Cuttsy

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links